Mayinglong Pharmaceutical Group Co Ltd (600993) - Net Assets
Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has net assets worth CN¥4.73 Billion CNY (≈ $692.62 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.64 Billion ≈ $825.21 Million USD) and total liabilities (CN¥906.06 Million ≈ $132.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mayinglong Pharmaceutical Group Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.73 Billion |
| % of Total Assets | 83.93% |
| Annual Growth Rate | 14.59% |
| 5-Year Change | 36.22% |
| 10-Year Change | 123.85% |
| Growth Volatility | 26.74 |
Mayinglong Pharmaceutical Group Co Ltd - Net Assets Trend (2001–2025)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 600993 company net worth.
Annual Net Assets for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual net assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025. Also explore net asset growth rate of Mayinglong Pharmaceutical Group Co Ltd to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.51 Billion ≈ $660.65 Million |
+7.46% |
| 2024-12-31 | CN¥4.20 Billion ≈ $614.78 Million |
+8.56% |
| 2023-12-31 | CN¥3.87 Billion ≈ $566.29 Million |
+6.94% |
| 2022-12-31 | CN¥3.62 Billion ≈ $529.55 Million |
+9.19% |
| 2021-12-31 | CN¥3.31 Billion ≈ $484.97 Million |
+12.48% |
| 2020-12-31 | CN¥2.95 Billion ≈ $431.18 Million |
+11.83% |
| 2019-12-31 | CN¥2.63 Billion ≈ $385.58 Million |
+12.04% |
| 2018-12-31 | CN¥2.35 Billion ≈ $344.15 Million |
+3.56% |
| 2017-12-31 | CN¥2.27 Billion ≈ $332.31 Million |
+12.60% |
| 2016-12-31 | CN¥2.02 Billion ≈ $295.13 Million |
+6.91% |
| 2015-12-31 | CN¥1.89 Billion ≈ $276.06 Million |
+11.05% |
| 2014-12-31 | CN¥1.70 Billion ≈ $248.58 Million |
+8.46% |
| 2013-12-31 | CN¥1.57 Billion ≈ $229.19 Million |
+9.28% |
| 2012-12-31 | CN¥1.43 Billion ≈ $209.74 Million |
+8.59% |
| 2011-12-31 | CN¥1.32 Billion ≈ $193.15 Million |
+17.10% |
| 2010-12-31 | CN¥1.13 Billion ≈ $164.95 Million |
+7.18% |
| 2009-12-31 | CN¥1.05 Billion ≈ $153.90 Million |
+20.69% |
| 2008-12-31 | CN¥871.43 Million ≈ $127.52 Million |
+2.15% |
| 2007-12-31 | CN¥853.12 Million ≈ $124.84 Million |
-0.24% |
| 2006-12-31 | CN¥855.21 Million ≈ $125.14 Million |
+43.36% |
| 2005-12-31 | CN¥596.55 Million ≈ $87.29 Million |
+8.03% |
| 2004-12-31 | CN¥552.20 Million ≈ $80.80 Million |
+138.69% |
| 2003-12-31 | CN¥231.35 Million ≈ $33.85 Million |
+13.11% |
| 2002-12-31 | CN¥204.54 Million ≈ $29.93 Million |
+18.91% |
| 2001-12-31 | CN¥172.01 Million ≈ $25.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mayinglong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7235.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.63 Billion | 82.82% |
| Other Components | CN¥752.38 Million | 17.18% |
| Total Equity | CN¥4.38 Billion | 100.00% |
Mayinglong Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vedant Fashions Limited
NSE:MANYAVAR
|
$1.43 Billion |
|
Prosegur
MC:PSG
|
$1.43 Billion |
|
American Superconductor Corporation
NASDAQ:AMSC
|
$1.43 Billion |
|
Clariane SE
PA:CLARI
|
$1.43 Billion |
|
BlackRock ESG Capital Allocation Trust
NYSE:ECAT
|
$1.43 Billion |
|
Wondershare Technology Co Ltd Class A
SHE:300624
|
$1.43 Billion |
|
Healthcare Services Group Inc
NASDAQ:HCSG
|
$1.43 Billion |
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
$1.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mayinglong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,065,961,926 to 4,379,741,754, a change of 313,779,828 (7.7%).
- Net income of 581,492,373 contributed positively to equity growth.
- Dividend payments of 269,648,111 reduced retained earnings.
- Other comprehensive income decreased equity by 299,764,141.
- Other factors increased equity by 301,699,708.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥581.49 Million | +13.28% |
| Dividends Paid | CN¥269.65 Million | -6.16% |
| Other Comprehensive Income | CN¥-299.76 Million | -6.84% |
| Other Changes | CN¥301.70 Million | +6.89% |
| Total Change | CN¥- | 7.72% |
Book Value vs Market Value Analysis
This analysis compares Mayinglong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 66.95x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.34 | CN¥22.67 | x |
| 2002-12-31 | CN¥0.41 | CN¥22.67 | x |
| 2003-12-31 | CN¥0.47 | CN¥22.67 | x |
| 2004-12-31 | CN¥1.21 | CN¥22.67 | x |
| 2005-12-31 | CN¥1.30 | CN¥22.67 | x |
| 2006-12-31 | CN¥1.42 | CN¥22.67 | x |
| 2007-12-31 | CN¥1.67 | CN¥22.67 | x |
| 2008-12-31 | CN¥1.83 | CN¥22.67 | x |
| 2009-12-31 | CN¥2.21 | CN¥22.67 | x |
| 2010-12-31 | CN¥2.38 | CN¥22.67 | x |
| 2011-12-31 | CN¥2.71 | CN¥22.67 | x |
| 2012-12-31 | CN¥2.97 | CN¥22.67 | x |
| 2013-12-31 | CN¥3.30 | CN¥22.67 | x |
| 2014-12-31 | CN¥3.66 | CN¥22.67 | x |
| 2015-12-31 | CN¥4.16 | CN¥22.67 | x |
| 2016-12-31 | CN¥4.50 | CN¥22.67 | x |
| 2017-12-31 | CN¥5.07 | CN¥22.67 | x |
| 2018-12-31 | CN¥5.28 | CN¥22.67 | x |
| 2019-12-31 | CN¥5.97 | CN¥22.67 | x |
| 2020-12-31 | CN¥6.60 | CN¥22.67 | x |
| 2021-12-31 | CN¥7.37 | CN¥22.67 | x |
| 2022-12-31 | CN¥8.11 | CN¥22.67 | x |
| 2023-12-31 | CN¥8.69 | CN¥22.67 | x |
| 2024-12-31 | CN¥9.47 | CN¥22.67 | x |
| 2025-12-31 | CN¥10.16 | CN¥22.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mayinglong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.28%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.04%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.24x
- Recent ROE (13.28%) is below the historical average (13.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 18.60% | 13.44% | 0.64x | 2.17x | CN¥12.74 Million |
| 2002 | 18.48% | 13.28% | 0.68x | 2.04x | CN¥15.11 Million |
| 2003 | 19.42% | 12.22% | 0.89x | 1.80x | CN¥19.30 Million |
| 2004 | 9.96% | 14.19% | 0.54x | 1.29x | CN¥-190.62K |
| 2005 | 10.55% | 14.59% | 0.53x | 1.36x | CN¥3.13 Million |
| 2006 | 11.89% | 13.35% | 0.49x | 1.83x | CN¥11.40 Million |
| 2007 | 18.57% | 24.32% | 0.50x | 1.52x | CN¥61.55 Million |
| 2008 | 10.30% | 9.93% | 0.70x | 1.49x | CN¥2.37 Million |
| 2009 | 18.93% | 17.62% | 0.71x | 1.51x | CN¥84.94 Million |
| 2010 | 11.98% | 10.40% | 0.81x | 1.42x | CN¥20.23 Million |
| 2011 | 11.94% | 9.83% | 0.85x | 1.44x | CN¥22.40 Million |
| 2012 | 13.47% | 11.27% | 0.84x | 1.43x | CN¥44.74 Million |
| 2013 | 13.07% | 11.63% | 0.79x | 1.42x | CN¥43.74 Million |
| 2014 | 12.83% | 12.43% | 0.74x | 1.39x | CN¥44.43 Million |
| 2015 | 12.51% | 12.52% | 0.74x | 1.35x | CN¥44.85 Million |
| 2016 | 12.90% | 11.90% | 0.84x | 1.29x | CN¥56.22 Million |
| 2017 | 14.60% | 18.28% | 0.64x | 1.26x | CN¥100.83 Million |
| 2018 | 7.76% | 8.02% | 0.75x | 1.29x | CN¥-50.87 Million |
| 2019 | 14.08% | 13.31% | 0.82x | 1.28x | CN¥104.27 Million |
| 2020 | 14.71% | 15.01% | 0.72x | 1.36x | CN¥134.12 Million |
| 2021 | 14.65% | 13.72% | 0.82x | 1.30x | CN¥147.45 Million |
| 2022 | 13.69% | 13.55% | 0.70x | 1.45x | CN¥128.95 Million |
| 2023 | 11.86% | 14.13% | 0.65x | 1.29x | CN¥69.45 Million |
| 2024 | 12.99% | 14.17% | 0.72x | 1.27x | CN¥121.50 Million |
| 2025 | 13.28% | 15.04% | 0.71x | 1.24x | CN¥143.52 Million |
Industry Comparison
This section compares Mayinglong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,755,273,774
- Average return on equity (ROE) among peers: -4.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mayinglong Pharmaceutical Group Co Ltd (600993) | CN¥4.73 Billion | 18.60% | 0.19x | $1.43 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $805.26 Million | -92.13% | 3.95x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $591.07 Million | 1.62% | 0.52x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.12 Billion | 13.25% | 0.26x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 7.85% | 0.81x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $210.25 Million | 11.37% | 0.23x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.74 Billion | -22.62% | 2.37x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $6.56 Billion | 20.83% | 0.09x | $3.07 Billion |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It a… Read more